Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.65 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.65 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.65 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260752 | 0.89 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL260760 | 0.88 | PI4KA (0.59) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL2291671 | 0.85 | PI4KA (0.80) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL22757346 | 0.83 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL23914964 | 0.82 | LMNA (0.65) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL18493278 | 0.82 | LMNA (0.65) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL17205571 | 0.82 | LMNA (0.65) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL24601301 | 0.82 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL24601294 | 0.82 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL24601293 | 0.82 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093380-B2 | Viricides, antitumor agents, anticancer agents | PHARMASSET, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-1545545-A4 | COMPOUNDS WITH THE BICYCLO 4.2.1 NONANE SYSTEM FOR THE TREATMENT OF i FLAVIVIRIDAE /i INFECTIONS | PHARMASSET INC (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1545545-A2 | COMPOUNDS WITH THE BICYCLO 4.2.1 NONANE SYSTEM FOR THE TREATMENT OF i FLAVIVIRIDAE /i INFECTIONS | Pharmasset, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040082574-A1 | Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections | PHARMASSET, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004013300-A2 | COMPOUNDS WITH THE BICYCLO[4.2.1]NONANE SYSTEM FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS | PHARMASSET INC. (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082574-A1 | Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections | CYP4B1, HAVCR2, CYP2S1 | PI4KA 187/4885PI4K2B 240/4885PI4K2A 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.